V.Ch. Kravtsov et al. / Journal of Molecular Structure 1017 (2012) 32–37
37
1H NMR: d, ppm, (DMSO-d6), (J, Hz): 7.32-7.68 (7H m, H-6, H-8,
H-9, H-30, H-40, H-50, H-60); 5.95 (1H s, H-4); 6.45 (1H s, H-5);
4.37–4.47 (1H, m, ACH2A(CH2)4ACH3); 4.69–4.75 (1H, m,
ACH2A(CH2)4ACH3); 1.23–1.50 (8H, m, ACH2A(CH2)4ACH3);
0.83 (3H t, J = 7.0, ACH3).
substitutient in position 1 of benzodiazepine fragment may allow
the fine tuning of such interaction. Moreover, the intermolecular
interaction may influence on conformation of seven-membered
ring in 1,4-benzodiazepines and this variation of conformation
parameters should be taken in account in attempts to establish
correlation between geometrical parameters and biological
activity.
3.2. X-ray crystallography
X-ray data for 2 and 3 were collected at 100 and 130 K with an
Acknowledgements
Xcalibur Oxford Diffraction diffractometer, equipped with a CCD
area detector and a graphite monochromator utilizing Mo K
a
This research was supported by joint award of State Agency on
Science, Innovation and Informatization of Ukraine (No. M/268-
2011) and Academy of Sciences of Moldova (10.820.09.13/UF).
radiation. Final unit cell dimensions were obtained and refined
on an entire data set. All calculations to solve the structures and
to refine the model were carried out with the programs SHELXS97
and SHELXL97 [21]. The C–bound H atoms were placed in calcu-
lated positions and were treated in a riding model approximation
with Uiso(H) = 1.2Ueq(C), while the OA and N-bound H–atoms of
hydroxyl and amino groups were found from difference Fourier
maps and were refined with isotropic displacement parameters
Uiso(H) = 1.5Ueq(O), Uiso(H) = 1.2Ueq(N). The Figures were produced
using Mercury [22]. Crystal data and details of the structure refine-
ment are given in Table 4. Selected geometric parameters for 2 and
3 are given in Tables 2 and 3. CCDC 858024, 858025 contain the
crystallographic data for 2–3. These data can be obtained free of
charge from The Cambridge Crystallographic Data Centre via
References
[1] G. Bandoli, D.A. Clemente, J. Chem. Soc. Perkin II. (1976) 413.
[2] W.L. Duax, C.M. Weeks, D.C. Rohrer, Topics in Stereochemistry, in: E.L. Elial, N.
Allinger (Eds.), vol. 9, 1976, p. 271.
[3] T.A. Hamor, I.L. Martin, Structure-activity relationships in a series of 5-phenyl-
1,4-benzodiazepines,, in: A.S. Horn, C.J. Ranter (Eds.), X-ray Crystallography
and Drug Action, Clarendon Press, Oxford, 1984, pp. 275–301.
[4] A.V. Bogatsky, S.A. Andronati, N. Ya Golovenko, Tranquillizers. 1.4-
Benzodiazepines and Related Structures [in Russian], Science Council, Kiev,
1980.
[5] A. Mozayani, L.P. Raymon, Handbook of drug interactions. A clinical and
forensic guide. New Jersey Humana Press Inc., Totowa NJ, 2004, 662 p.
[6] N.Ya. Golovenko, I.A. Kravchenko, Biokhimicheskaya farmakologiya
prolekarstv (Biochemical pharmacology of prodrugs), Odessa, Ekologia, 2007,
360 p.
[7] S.A. Andronati, I.A. Prokopenko, A.S. Yavorsky, Yu.A. Simonov, A.A. Dvorkin,
T.Sh. Gifeisman, V.M. Chepelev, Pharmazie 43 (1988) 730.
[8] V.I. Pavlovsky, E.A. Semenishina, S.A. Andronati, I.G. Filippova, Yu.A. Simonov,
M. Gdaniec, J. Lipkowski, Chem. Heterocycl. Comp. 45 (2009) 1379.
[9] R. Ian Fryer, J. Heterocycl. Chem. 9 (1972) 744.
[10] S.C. Bell, S.J. Childress, J. Org. Chem. 27 (1962) 1691.
[11] A. Stempel, I. Douvan, E. Reeder, L.H. Sternbach, J. Org. Chem. 32 (1967) 2417.
[12] J. Lipkowski, K.S. Andronati, Yu.A. Simonov, V.Ch. Kravtsov, J. Struct. Chem. 46
(2005) 116.
[13] A.A. Mazurov, A.A. Dvorkin, Yu. A. Simonov, S.A. Andronati, Khim. Get. Soedin.,
SSSR (Russ.) Chem. Heterocycl. Compd., 1990, p. 685.
[14] A.A. Karapetyan, V.G. Andrianov, Yu.T. Struchkov, A.V. Bogatskii, S.A.
Andronati, T.I. Korotenko, Bioorg. Khim. 5 (1979) 1684.
[15] G.B. Sergeev, B.M. Sergeev, Y.N. Morosov, V.V. Chernyshev, Acta Cryst. E66
(2010) o2623.
[16] G. Gilli, V. Bertolasi, M. Sacerdoti, P.A. Borea, Acta Crystallogr. B33 (1977) 2664.
[17] M.C. Etter, Israel J. Chem. 25 (1985) 312.
[18] Y. Lu, Y. Wang, W. Zhu, Phys. Chem. Chem. Phys. 12 (2010) 4543.
[19] M.D. Prasanna, T.N. Guru Row, Cryst. Eng. 3 (2000) 135.
[20] Ishu Saraogi, V.G. Vijay, Soma Das, K. Sekar, T.N. Guru Row, Cryst. Eng. 6 (2003)
69.
4. Conclusion
7-Bromo-5-(20-chloro)phenyl-3-hydroxy-1-methyl-1,2-dihydro
-3H-1,4-benzodiazepin-2-one and 7-bromo-5-(20-chloro)phenyl-
1-hexyl-1,2,4,5-tetrahydro-3H-1,4-benzodiazepin-2,3-dione were
obtained by alkylation of 7-bromo-5-(20-chloro)phenyl-3-hydroxy
-1,2-dihydro-3H-1,4-benzodiazepin-2-one, and their crystal struc-
tures were determined by single crystal X-ray diffraction. Redistri-
bution of hydrogen atoms in the core of the molecules resulted in
different self-association hydrogen-bonded patterns in two com-
pounds. The availability of two crystallographically independent
molecules and co-existence of two different associating chains
either only via Oꢀ ꢀ ꢀBr interactions or combination of H-bonds
and halogen–
p
interactions in 7-bromo-5-(20-chloro)phenyl-3-
hydroxy-1-methyl-1,2-dihydro-3H-1,4-benzodiazepin-2-one might
be considered as a prerequisite for the possible polymorphism in
this system as well as indicates the diverse modes of interaction
of 1,4-benzodiazepines with various receptors. The selection of
[21] G.M. Sheldrick, Acta Crystallogr. A64 (2008) 112.
[22] C.F. Macrae, P.R. Edgington, P. McCabe, E. Pidcock, G.P. Shields, R. Taylor, M.
Towler, J. van de Streek, J. Appl. Crystallogr. 39 (2006) 453.